Skip to main content

Table 2 General patterns of treatment according to study population

From: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

  All patients Patients alive at 5 years Patients treated with chemotherapy
  (n = 2165) (n = 224) (n = 1575)
  n % n %   
Metastatic treatment received
 Best supportive care only 340 15.70 13 5.80 0 0.00
 Locoregional treatment 1054 48.68 187 83.48 804 51.05
  Surgery 408 38.71 82 43.85 282 35.07
  Radiotherapy 254 24.10 12 6.42 213 26.49
  Radiofrequency 42 3.98 9 4.81 33 4.10
  Other 30 2.85 3 1.60 19 2.36
  Combination 320 30.36 81 43.32 257 31.97
  None 1111 51.32 37 16.52 771 48.95
 Chemotherapy 1575 72.75 156 69.64 1575 100
  None 590 27.25 68 30.36
  1 line 489 22.59 54 34.62 489 31.05
  2 lines 293 13.53 24 15.38 293 18.60
  3 lines 240 11.09 21 13.46 240 15.24
  4 lines 157 7.25 11 7.05 157 9.97
   > 4 lines 396 17.27 46 29.49 396 25.15
Anthracycline received
 Yes 109 69.87 951 60.38
 No 47 30.13 624 39.62
Anthracycline received as first line
 Yes 98 62.82 852 54.10
 No 58 37.18 723 45.90
Polychemotherapy received as first line
 Yes 95 60.90 716 45.46
 No 61 39.10 859 54.54
Inclusion in a clinical trial
 Yes: 55 35.26 332 21.08
 Line 1 10 6.41 122 7.75
 Line 2 17 16.67 107 9.85
 Line 3 10 12.82 56 7.06
 Line 4 7 12.28 30 5.42
 Other lines 11 23.91 17 4.29
 No 101 64.74 1243 78.92
Off-label drugs
 Yes: 99 63.46 810 51.43
 Line 1 21 13.46 194 12.32
 Line 2 22 21.57 203 18.69
 Line 3 14 17.95 169 21.31
 Line 4 21 36.84 142 25.68
 Other lines 21 45.65 102 25.76
 No 57 36.54 765 48.57